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Renal fibrosis represents a common pathway leading to progression of chronic kidney
disease. Renal interstitial fibrosis is characterized by extensive fibroblast activation
and excessive production and deposition of extracellular matrix (ECM), which leads
to progressive loss of kidney function. There is no effective therapy available clinically
to halt or even reverse renal fibrosis. Although activated fibroblasts/myofibroblasts
are responsible for the excessive production and deposition of ECM, their origin
remains controversial. Recent evidence suggests that bone marrow-derived fibroblast
precursors contribute significantly to the pathogenesis of renal fibrosis. Understanding
the molecular signaling mechanisms underlying the recruitment and activation of the
bone marrow-derived fibroblast precursors will lead to novel therapy for the treatment
of chronic kidney disease. In this review, we summarize recent advances in our
understanding of the recruitment and activation of bone marrow-derived fibroblast
precursors in the kidney and the development of renal fibrosis and highlights new insights
that may lead to novel therapies to prevent or reverse the development of renal fibrosis.
Keywords: chemokine, cytokine, circulating fibroblast precursors, fibroblasts, renal fibrosis, extracellular matrix,
chronic kidney disease, monocyte-to-fibroblast transition
INTRODUCTION
Chronic kidney disease (CKD) is a global public health problem. Worldwide, over 1 million
people die from CKD yearly. It is estimated that more than 20 million Americans have CKD
and more than 450,000 Americans suffer from end-stage renal disease (ESRD) requiring renal
replacement therapy. CKD has become the eighth leading cause of death in the United States.
Regardless of various etiologies, a common pathological feature of CKD is renal fibrosis, which
is characterized by accumulation of fibroblasts/myofibroblasts with increased production and
deposition of extracellular matrix (ECM) including collagen type I, III, IV, fibronectin, vimentin,
and proteoglycans (Zeisberg and Neilson, 2010; Conway and Hughes, 2012; Farris and Colvin,
2012). It is generally agreed that activated fibroblasts termed myofibroblasts are the principle cells
responsible for the increase ECM production and deposition, the origin of these matrix-producing
cells remains debatable. They were traditionally thought to arise from resident interstitial fibroblasts
(Qi et al., 2006; Picard et al., 2008). Recent evidence indicate that they may originate from
epithelial/endothelial-to-mesenchymal transition (Iwano et al., 2002; Zeisberg and Kalluri, 2004;
Zeisberg et al., 2008; Liu, 2010), pericytes (Lin et al., 2008), and bone marrow-derived fibroblast
precursors termed fibrocytes (Grimm et al., 2001; Sakai et al., 2006; Broekema et al., 2007;
Niedermeier et al., 2009; Chen et al., 2011).
In response to kidney injury, multiple cell types in the circulation are recruited to the site of
injury to participate in a wound healing response. A dysregulated wound healing process causes
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fibrosis, where ECM and fibroblasts replace normal renal
parenchyma and lead to kidney dysfunction. Therefore,
investigations of underlying mechanisms and identification of
novel therapeutic targets of renal fibrosis will have huge impact
on patient survival, global health, and economic burden. Fibrosis
is a complex and progressive pathological process involving
infiltration of mononuclear cells including bone marrow-derived
fibroblast precursors (fibrocytes), macrophages, and immune
cells, which suggest that interaction and communication among
these cell types regulates the development of fibrotic disorders
(Kisseleva and Brenner, 2008; Wynn, 2008). Because activated
fibroblasts are the principal effector cells that mediate ECM
production in the fibrotic kidney disease, their activation is
regarded as an important event in the pathogenesis of renal
fibrosis (Eddy, 2005; Neilson, 2006). However, the origin
of the activated fibroblasts has been controversial. They are
traditionally thought to arise from resident fibroblasts within the
kidney. Recent studies have shown that the activated fibroblasts
may originate from bone marrow-derived fibroblast precursors
(Grimm et al., 2001; Iwano et al., 2002; Sakai et al., 2006;
Broekema et al., 2007; Chen et al., 2011). In a clinical study of
mismatched kidney transplantation in humans, the proportion
of host-derived smooth muscle actin (SMA)-positive cells is
∼30% in allografts undergoing chronic rejection compared with
10% in those without rejection (Grimm et al., 2001). In rodent
models of renal fibrosis, we and others have shown that bone
marrow-derived fibroblasts migrate into the kidney in response
to injury (Iwano et al., 2002; Roufosse et al., 2006; Broekema
et al., 2007; Chen et al., 2011; Xia et al., 2014b). For example, one
study using bone marrow transplantation of transgenic mice that
express enhanced green fluorescence protein (GFP) under the
control of the fibroblast specific protein 1 (FSP1) promoter has
demonstrated that 15% of bone marrow-derived fibroblasts are
present in the kidney 10 days after obstructive injury (Iwano et al.,
2002). Using bone marrow transplantation of transgenic rats that
express human placental alkaline phosphatase, Broekema et al.
have shown that more than 30% α-SMA positive myofibroblasts
are derived from bone marrow 7 days after ischemia-reperfusion
injury (Broekema et al., 2007). Using chimeric mice transplanted
with GFP-expressing bone marrow cells, Li et al have reported
that more than 30% of renal α-SMA+ myofibroblasts are
derived from the bone marrow in a mouse adriamycin-induced
fibrosis model (Li et al., 2007). Recently, Lebleu et al. have
demonstrated that 35% α-SMA positive myofibroblasts are
derived from bone marrow 10 days after obstructive injury
using bone marrow transplantation of transgenic mice express
red fluorescence protein (RFP) driven by α-SMA (Lebleu et al.,
2013). Using bone marrow transplantation of transgenic mice
that express GFP driven by collagen 1A1 promoter, we have
shown that bone marrow-derived hematopoietic fibroblasts
migrate into the kidney, proliferate, and differentiate into
α-SMA+ myofibroblasts (Xia et al., 2014b). In contrast, one
study reported that bone marrow-derived GFP+ fibroblasts
contribute to a minor fraction of myofibroblasts (Lin et al.,
2008). Another study reported that bone marrow-derived cells
do not contribute significantly to collagen synthesis using bone
marrow transplantation of transgenic mice that express luciferase
and β-galactosidase driven by collagen 1A2 promoter (Roufosse
et al., 2006). One potential pitfall of bone marrow transplantation
is the bone marrow engraftment rate. Furthermore, detection of
GFP, luciferase, or β-galactosidase in tissue can be technically
demanding. Therefore, it is difficult to interpret negative data
obtained with these reporter mice. To objectively quantify the
number of hematopoietic fibroblasts in the kidney, we stained
freshly-isolated kidney cells with CD45, a hematopoietic cell
marker, and collagen I, a mesenchymal cell marker, and examined
with flow cytometry. The results have shown that CD45+ and
collagen I+ cells constituted 45% of total collagen I+ cells in the
kidney 7 days after obstructive injury (Xia et al., 2014b). Using
lineage tracing and adoptive transfer, Wang et al. have recently
reported that monocytes/macrophages from bone marrow can
transform into myofibroblasts via macrophage-to-myofibroblast
transition (Wang et al., 2015). Therefore, compelling evidence
indicate that bone marrow-derived fibroblasts contribute
significantly to the pathogenesis of renal fibrosis and suggest
targeting bone marrow-derived fibroblasts may represent a novel
therapeutic strategy for the treatment of fibrotic kidney disease
and possible fibrotic disorders of other organs.
RECRUITMENT OF BONE
MARROW-DERIVED FIBROBLAST
PRECURSORS
The recruitment of circulating cells into sites of injury is
mediated by locally produced chemokines. Chemokines are
classified based on the relative position of cysteine residues
near the NH2 terminus into four major families: CC, CXC, C,
and CX3C (Rollins, 1997; Mackay, 2001). Recent studies have
shown that chemokines and their receptors play an important
role in the recruitment of bone marrow-derived fibroblast
precursors into the kidney in response to injury. CCL21/CCR7,
CXCL16/CXCR6, CCR2 are involved in recruiting circulating
fibroblast precursors into the kidney (Table 1) (Sakai et al., 2006;
Chen et al., 2011; Reich et al., 2013; Xia et al., 2013a,b, 2014a,b).
The chemokine CXCL16 is a recently discovered cytokine
belonging to the CXC chemokine family (Matloubian et al.,
2000; Wilbanks et al., 2001). It was originally described as a
scavenger receptor for phosphatidylserine and oxidized low-
density lipoprotein (SR-PSOX; Shimaoka et al., 2000). There
are two forms of CXCL16. The transmembrane form is a type
I transmembrane glycoprotein consisting of an extracellular
N-terminal chemokine domain, glycosylated mucin-like stalk,
transmembrane-spanning region, and a short cytoplasmic
domain, with a YXPV motif that is a potential tyrosine-
phosphorylation and SH2-protein-binding site (Izquierdo et al.,
2014). The transmembrane form functions as an adhesion
molecule for CXCR6 expressing cells and scavenger receptor for
oxidized low-density lipoprotein (Shimaoka et al., 2000, 2004).
The soluble form generated by its cleavage at the cell surface
functions as a chemoattractant to recruit circulating cells (Gough
et al., 2004). CXCL16 is induced in kidney tubular epithelial cells
in vivo in a murine model of renal fibrosis induced by obstructive
injury (Okamura et al., 2007; Chen et al., 2011). Tumor necrosis
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TABLE 1 | Chemokines and their receptors in the recruiment of bone marrow-derived fibroblast precusors or fibrocytes.
Chemokines/Receptors Methods Models Effect on fibrosis References
CCL21/CCR7 Anti-CCL21 antibody CCR7 knockout mice UUO 40–50% reduction Sakai et al., 2006
CXCL16 CXCL16 knockout mice UUO 40–50% reduction Chen et al., 2011
CCR2 CCR2 knockout mice, depletion of fibrocytes, BMT UUO 20–30% reduction Reich et al., 2013
CCR2 CCR2 knockout mice UUO 30–40% reduction Xia et al., 2013a
CXCL16 CXCL16 knockout mice Angiotensin II infusion 40–50% reduction Xia et al., 2013b
CXCR6 CXCR6 knockout mice, BMT Angiotensin II infusion 40–50% reduction Xia et al., 2014a
CXCR6 CXCR6 knockout mice, BMT UUO, IRI 40–50% reduction Xia et al., 2014b
BMT, bone marrow transplantation; IRI, ischemia-reperfusion injury; UUO, unilateral ureteral obstruction.
factor (TNF)-α and interferon (IFN)-γ upregulate CXCL16
expression in tubular epithelial cells in vitro (Xia et al., 2013a). In
addition, the TNF superfamily cytokine TNF-like weak inducer
of apoptosis (TWEAK) increases CXCL16 expression in kidney
tubular epithelial cells in vitro and in vivo (Izquierdo et al.,
2012). Interestingly, angiotensin II, a key promoter of kidney
injury, also enhances CXCL16 expression in tubular epithelial
cells via activation of NF-kB, a master regulator of inflammation
(Xia et al., 2013b). We have recently studied the functional role
of CXCL16 in the pathogenesis of renal fibrosis in a murine
model of obstructive nephropathy using CXCL16 knockout mice.
Our results have shown that bone marrow-derived fibroblast
precursor infiltration, myofibroblast activation, and ECMprotein
deposition are reduced in the obstructed kidneys of CXCL16-
knockout mice (Chen et al., 2011). These data indicate that
CXCL16 promotes renal fibrosis by recruiting bone marrow-
derived fibroblast precursors. More recently, we have examined
the functional role of CXCL16 in angiotensin II-induced renal
injury and fibrosis. Our results have demonstrated that genetic
deletion of CXCL16 protects the kidney from angiotensin
II infusion-induced renal dysfunction, inhibits renal fibrosis,
reduces proteinuria, suppresses bone marrow-derived fibroblast
accumulation, myofibroblast formation, macrophage, and T cell
infiltration and pro-inflammatory cytokine expression without
affecting blood pressure at baseline or in response to angiotensin
II infusion (Xia et al., 2013b). In support of clinical relevance
of these observations in experimental animal models, clinical
studies have shown that circulating CXCL16 is elevated in
patients with CKD and diabetic nephropathy and high levels of
CXCL16 are associated with CKD progression and development
of proteinuria (Lin et al., 2011; Zhao et al., 2014).
CXCR6 is the receptor for CXCL16. CXCR6 was first cloned
as an orphan receptor by three independent groups and was
termed STRL33, BONZO, or TYMSTR (Alkhatib et al., 1997;
Deng et al., 1997; Loetscher et al., 1997). We have recently shown
that both circulating fibroblast precursors and bone marrow-
derived fibroblasts in the kidney express CXCR6 (Chen et al.,
2011; Xia et al., 2014b). Genetic disruption of CXCR6 reduces
the recruitment of bone marrow-derived fibroblast precursors
into the kidney and the development of renal fibrosis induced
by ureteral obstruction, ischemia-reperfusion, and angiotensin II
infusion (Xia et al., 2014a,b).
In these studies, we have observed that genetic deficiency
of CXCL16 or CXCR6 does not completely block bone
marrow-derived fibroblast precursor infiltration into the
kidney and renal fibrosis development, suggesting that other
chemokine/receptor pairs may be involved in the process of
recruiting bone marrow-derived fibroblast precursors into the
kidney. Consistent with this notion, CCR2 and CCL21/CCR7
have been reported to play a role in the recruitment of bone
marrow-derived fibroblast precursors into the kidney and
the development of renal fibrosis (Sakai et al., 2006; Reich
et al., 2013; Xia et al., 2013a). Interestingly, the expression of
CXCL16 in the kidney is reduced in CCR2 knockout mice in
response to obstructive injury, suggesting the interaction of two
distinct chemokine systems modulates renal tubular epithelial
cell-initiated fibrosis (Xia et al., 2013a).
ACTIVATION OF BONE MARROW-DERIVED
FIBROBLAST PRECURSORS
TGF-β1/Smad3
The activation of bone marrow derived fibroblast precursors
plays a crucial role in the pathogenesis of renal fibrosis
(Yang et al., 2013; Chen et al., 2014). Myofibroblasts are a
population of smooth muscle-like fibroblasts that express α-
smooth muscle actin (α-SMA; Powell et al., 1999). The activation
of myofibroblasts is generally considered a main event in
the pathogenesis of renal fibrosis (Nath, 1992; Eddy, 2013).
Furthermore, experimental and clinical studies have shown
that the number of interstitial myofibroblasts is associated
closely with the severity of tubulointerstitial fibrosis and the
rapidity of kidney disease progression (Zhang et al., 1995;
Essawy et al., 1997; Roberts et al., 1997). The activation of
bone marrow-derived fibroblast precursors are regulated by
locally produced cytokines (Yang et al., 2013; Chen et al.,
2014). TGF-β1 is a key profibrotic cytokine that play an
important role in the pathogenesis of renal fibrosis through
activation of a cascade of intracellular signaling pathways
(Border et al., 1990; Border and Noble, 1994; Böttinger and
Bitzer, 2002; Lan, 2011). Evidence suggests that activation
of the canonical Smad signaling cascade plays an important
role in stimulating ECM protein expression and tissue fibrosis
(Verrecchia et al., 2001; Zhao et al., 2002; Sato et al., 2003;
Latella et al., 2009; Huang et al., 2010; Meng et al., 2015).
We have recently examined the functional role of Smad3 in
the activation of bone marrow-derived fibroblast precursors in
vitro and in vivo (Chen et al., 2014). In cultured monocytes,
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TGF-β1 activates Smad3. Smad3 deficient monocytes express
less amount ECM proteins at baseline and Smad3 deficiency
completely abolished TGF-β1-induced expression of α-SMA
and extracellular matrix proteins in cultured monocytes in
vitro. Smad3-knockout mice accumulate significantly fewer bone
marrow-derived fibroblasts in the kidney after obstructive injury,
exhibit less myofibroblast activation, and express less α-SMA in
the obstructed kidney. Furthermore, genetic deletion of Smad3
reduces total collagen deposition and suppresses expression
of extracellular matrix proteins. Additionally, wild-type mice
engrafted with Smad3−/− bone marrow cells displayed fewer
bone marrow-derived fibroblasts in the kidney with obstructive
injury and showed less severe renal fibrosis compared with wild-
type mice engrafted with Smad3+/+ bone marrow cells. These
results indicate that Smad3 of bone marrow-derived cells plays
an important role in bone marrow-derived fibroblast activation.
However, Samd3 deficiency does not completely abolish bone
marrow-derived fibroblast activation, collagen deposition, and
ECM protein expression in vivo. These results suggest that
other factors may be involved in bone marrow-derived fibroblast
activation.
JAK3/STAT6
The activation of bone marrow-derived fibroblasts is modulated
by inflammatory cells in the microenvironment. T cells plays an
important role in the pathogenesis of renal fibrosis (Tapmeier
et al., 2010), which have been reported to regulate bone
marrow-derived fibrocyte activation (Niedermeier et al., 2009).
Naïve CD4+ T cells can differentiate into two major distinct
phenotypes, Th1 and Th2 cells, which are characterized by
specific cytokine expression patterns (Wynn, 2004). Th2 cells
produce Th2 cytokines such as IL-4 and IL-13, which induce
alternative activation of macrophage and promotes monocyte-
to-fibroblast transition, Th1 cells produces Th1 cytokines such
as IFN-γ and IL-12, which promote classical activation of
macrophages and inhibit fibrocyte differentiation (Wynn, 2004;
Shao et al., 2008). However, the molecular signaling mechanisms
by which Th2 cytokines promote bonemarrow-derived fibroblast
activation are not known. We have found that JAK3/STAT6
signaling pathway is activated during the development of renal
fibrosis and plays an important role in bone marrow-derived
fibroblast activation, extracellular matrix protein production, and
interstitial fibrosis development (Yan et al., 2015). Specifically,
our results have shown that Th2 cytokine—IL-4 or IL-13 induces
STAT6 activation and stimulates bone marrow monocytes to
express ECM proteins and α-smooth muscle actin (α-SMA).
CP690550, a JAK3-specific inhibitor, or STAT6 deficiency inhibits
IL-4/IL-13-indcued STAT6 activation and expression of ECM
proteins and α-SMA in bone marrow monocytes in vitro.
Furthermore, CP690550 treatment or STAT6 deficiency inhibits
bone marrow-derived fibroblast activation and ECM protein
production in the kidney in response to obstructive nephropathy.
To further confirm the role of bone marrow STAT6 signaling
in myeloid fibroblast activation, we performed bone marrow
chimeric experiments. Wild-type mice transplanted with STAT6
null bone marrow cells exhibit fewer bone marrow-derived
fibroblasts and develop a lesser degree of renal fibrosis. These
results suggest that inhibition of JAK3/STAT6 signaling may
serve as a novel therapeutic target for fibrotic kidney disease.
Adiponectin/AMPK
Adiponectin is a multifunctional cytokine and an important
regulator of lipid and carbohydrate metabolism. Emerging
evidence suggests that circulating adiponectin levels are elevated
in patients with CKD, and a high level of adiponectin is
linked to increased cardiovascular mortality (Zoccali et al.,
2003; Shimotomai et al., 2005; Iwashima et al., 2006; Zoccali
and Mallamaci, 2011; Mills et al., 2013). We have discovered
that adiponectin is induced following ischemia-reperfusion
and obstructive injury (Yang et al., 2013). Genetic deletion
of adiponectin inhibits bone marrow-derived fibroblast
accumulation and myofibroblast activation. Furthermore,
adiponectin deficiency also reduces the expression of profibrotic
chemokines and cytokines and the production of ECM protein in
the kidneys following obstructive injury or ischemia-reperfusion.
These results indicate that adiponectin plays a significant
role in the activation and maturation of bone marrow-derived
fibroblasts and the development of renal fibrosis.Mechanistically,
adiponectin stimulated α-SMA and extracellular matrix protein
expression in bone marrow-derived monocytes via activation of
adenosine monophosphate-activated protein kinase (AMPK).
AMPK inhibition with a pharmacological inhibitor (compound
C) or dominant negative AMPK-α1 attenuated adiponectin-
induced expression of α-SMA and extracellular matrix proteins.
Furthermore, AMPK activation with 5-aminoimidazole-4-
carboxamide-riboside (AICAR), a cell permeable adenosine
analog (Corton et al., 1995), resulted in increased expression
of α-SMA and extracellular matrix proteins. These results
indicate that adiponectin is a critical regulator of monocyte-to-
fibroblast transition and renal fibrosis. Therefore, inhibition of
adiponectin/AMPK signaling may represent a novel therapeutic
target for fibrotic kidney disease.
It is generally thought that macrophages do not produce ECM
proteins. These cells promote fibrosis indirectly by producing
profibrotic cytokines that activate fibroblasts (Wynn and Barron,
2010). Recently, a model of two major macrophage classes
has been proposed. Classically activated macrophages exhibit a
Th1-like phenotype and promote inflammation in response to
Th1 cytokines; while alternatively activated macrophages or M2
macrophages display a Th2-like phenotype and stimulate ECM
production in response to Th2 cytokines (Gordon and Martinez,
2010). M2 macrophages are characterized by expressing MHC
class II, mannose receptor (CD206), Fizz1/Relm-α, and arginase.
Alternatively activated macrophages are implicated in the
fibrogenesis of other organs (Gordon and Martinez, 2010). The
functional role of macrophages has been intensively investigated
using a variety of depletion/blocking strategy in the UUO model
of renal fibrosis. Kitagawa et al. reported that genetic deletion of
CCR2 or treatment with CCR2 inhibitors reduces the infiltration
of F4/80-positive macrophages into the kidney and attenuates the
development of renal fibrosis (Kitagawa et al., 2004). Depletion
of macrophages using CD11b-DTR mice reduces myofibroblast
accumulation and the degree of renal fibrosis through regulation
of galectin-3 expression in the kidney (Henderson et al.,
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FIGURE 1 | A proposed model of signaling mechanisms underlying recruitment and activation of bone marrow-derived fibroblasts in renal fibrosis. In
response to injury (urinary tract obstruction, ischemia-reperfusion, hypertension), tubular epithelial cells produce chemokines CCL21/CXCL16/CCL2 and cytokine
TGF-β1. Chemokines act concertedly to recruit bone marrow-derived cells (T cells, monocytes, and fibrocytes) via interaction with their respective receptors. TGF-β1
activates Smad3 to stimulate monocyte-to-fibroblast transition. Th2 cells produce Th2 cytokines, which activate JAK3/STAT6 signaling pathway to promote
monocyte-to-fibroblast transition. Finally, adiponectin produced by infiltrating inflammatory cells regulates chemokine and cytokine production and stimulates
monocyte-to-fibroblast transition through activation of AMPK. T, T cells; M, Monocytes; MF, Myeloid fibroblasts.
2008). Interestingly, Galectin-3 has been shown to promote M2
macrophage polarization (MacKinnon et al., 2008). Selectively
depletion of F4/80-positive cells with liposome clodronate
attenuates the development of renal fibrosis, which is associate
with a reduction of TNF-α and TGF-β gene expression (Kitamoto
et al., 2009). However, not all macrophage depletion/inhibition
strategies result in a reduction of renal fibrosis in the UUO
model. Depletion of leukocyte with cyclophosphamide increases
the degree of renal fibrosis, which is attenuated by adoptive
transfer of macrophages (Nishida et al., 2005). Furthermore,
inhibition of macrophage colony-stimulating factor receptor
kinase reduces macrophage accumulation and tubular apoptosis
without affecting the development of renal fibrosis (Ma et al.,
2009). These studies may reflect the functional heterogeneity
of the macrophage subsets. We have recently demonstrated
for the first time that alternatively activated macrophages
produce procollagen I, suggesting a link betweenM2macrophage
polarization and monocyte-to-fibroblast transition (Yang et al.,
2013). Consistent with this novel concept, we have shown that
adiponectin deficiency suppresses M2 macrophage polarization
and inhibits the number of collagen-expressing M2 macrophages
in the injured kidneys (Yang et al., 2013). Therefore, macrophages
can participate in the pathogenesis of renal fibrosis via direct and
indirect mechanisms (Meng et al., 2014; Nikolic-Paterson et al.,
2014).
Renin Angiotensin System
Recent studies have shown that renin angiotensin system plays
an important role in the development of fibrotic kidney disease
(Mezzano et al., 2001). Inhibition of renin angiotensin system
with ACE inhibitors or angiotensin type 1 blockers attenuates
experimental renal fibrosis development in animals and retards
CKD progression in humans (Ishidoya et al., 1995; Brenner et al.,
2001). Sakai et al. have examined the role of renin angiotensin
system in the regulation of fibrocytes in murine models of
renal fibrosis (Sakai et al., 2008). Their results have shown
that inhibition of angiotensin II type 1 receptor (AT1R) with
valsantan reduces the number of fibrocytes in the kidney and
bone marrow and inhibits the development of renal fibrosis. In
contrast, angiotensin II type 2 receptor (AT2R) knockout mice
exhibit increased number of fibrocytes in the kidney and bone
marrow and develop more severe renal fibrosis. Furthermore,
inhibition of AT1R with valsantan decreases angiotensin II-
induced collage type I and TGF-β1 expression while inhibition of
AT2R increases angiotensin II-induced collage type I and TGF-
β1 expression in cultured fibrocytes. This study indicates that
angiotensin II receptors play opposite role in the development
and activation of fibrocytes. Further studies are needed to dissect
the downstream signaling mechanisms underlying angiotensin
II-induced fibrocyte activation.
CONCLUSION
Recent studies have demonstrated that bone marrow derived
fibroblast precursors contribute significantly to the pathogenesis
of renal fibrosis. Recruitment and activation of bone marrow-
derived fibroblasts are mediated through the interaction between
chemokines/cytokines and their receptors (Figure 1). Therefore,
targeting the signaling machinery of these chemokines/cytokines
could represent novel therapeutic strategy for the treatment of
renal fibrosis and possible fibrotic disorders of other organs.
FUTURE PERSPECTIVE
Although chemokines are involved in recruiting bone marrow-
derived fibroblasts into the kidney in response to injury,
the molecular signaling mechanisms underlying chemokines-
induced bone marrow-derived fibroblast recruitment remains to
be defined. Ras proteins are members of a family of small GTPase
that control signaling pathways involved in cell migration,
proliferation, differentiation, and survival (Rodríguez-Pena et al.,
2005). There are three Ras proteins, H-Ras, K-Ras, and N-Ras.
These Ras proteins are ubiquitously expressed including the
kidney. Recent studies have shown that Ras proteins are involved
in the development of renal fibrosis. Grande et al. have reported
that genetic gelation of H-Ras inhibits myofibroblast activation
and renal fibrosis development following ureteral obstruction in
mice (Grande et al., 2010). Future studies are needed to define
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the role of Ras signaling in the regulation of fibrocyte migration,
proliferation, and differentiation.
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